The Trump administration's move to end subsidies for Medicare drug plans could cost consumers
The Trump administration is ending temporary subsidies for Medicare Part D drug plans a year earlier than planned, a move expected to increase premiums for millions of seniors. Officials argue the subsidies are no longer necessary, while policy experts warn of significant cost increases for consumers.
Why it matters
Changes to Medicare subsidies directly affect the affordability of prescription drugs for millions of elderly Americans.
The Trump administration is ending subsidies that helped keep costs down for Medicare drug coverage. The change could mean higher Medicare Part D premiums for millions of beneficiaries in 2027.
Under the Inflation Reduction Act of 2022, Medicare patients' out-of-pocket drug spending was capped at $2,000 starting in 2025, and it changed the way insurers pay for drugs.
Living Better How to navigate the maze of drug discounts to get the best price That meant that while seniors would have to pay less at the pharmacy counter and therefore have easier access to expensive prescription drugs, insurers would be on the hook for more of the bill.
At first, insurers didn't know how much more they'd be spending — or how high to set premiums. To ease the transition for insurers, the Biden administration created temporary subsidies to stabilize premiums through what's called a demonstration project.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in